Biological markers (biomarkers) play a key role in drug development, regulatory approval and clinical care of patients and are linked to clinical and surrogate outcomes. Both acromegaly and Growth Hormone Deficiency (GHD) are pathological conditions related to important comorbidities that, in addition to having stringent diagnostic criteria, require valid markers for the definition of treatment, treatment monitoring and follow-up. GH and insulin-like growth factor-I (IGF-I) are the main biomarkers of GH action in children and adults while, in acromegaly, both GH and IGF-I are established biomarkers of disease activity. However, although GH and IGF-I are widely validated biomarkers of GHD and acromegaly, their role is not completely exhaustive or suitable for clinical classification and follow-up. Therefore, new biological markers for acromegaly and GH replacement therapy are strongly needed. The aim of this paper is to review and summarize the current state in the field pointing out new potential biomarkers for acromegaly and GH use/abuse.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0929866527666200420103816 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Acromegaly, although rare, is associated with multiple manifestations and complications; its high morbidity and mortality makes it a challenge. Treatment involves surgery and pharmacological therapies, focusing on biochemical normalization. This study analyzes the biochemical control in Colombian patients with acromegaly, seeking to improve the understanding of the effects of treatments in the management of the disease.
View Article and Find Full Text PDF[Diagnosis and clinicopathological analysis of pituitary neuroendocrine tumors based on the 5th WHO classification].
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, the First Affiliated Hospital of University of Science and Technology of China/Anhui Provincial Hospital, Hefei230036, China.
Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.
Front Endocrinol (Lausanne)
January 2025
Department and Clinic of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wrocław, Poland.
Article Synopsis
- Acromegaly is marked by increased bone turnover and higher vertebral fracture risk, with sclerostin inhibiting bone formation and playing a role in the OPG/RANK-L system that regulates bone metabolism.
- The study investigated levels of sclerostin, osteoprotegerin (OPG), and RANK-L in 126 patients with varying acromegaly activity, aiming to explore connections between sclerostin and bone health.
- Results showed lower sclerostin levels in acromegaly patients compared to controls, with notable differences in OPG levels across groups but no significant changes in RANK-L; a positive correlation was found between sclerostin and OPG in patients with various acromegaly
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly.
Pituitary
December 2024
Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS San Raffaele Hospital, Milan, Italy.
Introduction: First-generation somatostatin receptor ligands (fg-SRLs) are the cornerstone of acromegaly treatment. Additional benefits were shown using high dose (HD) or high frequency (HF), relatively short-term regimens. Although several predictors of response to standard dose (SD)-fg-SRLs were reported, outcome biomarkers for HF administration are not yet available.
View Article and Find Full Text PDFIGF-1 levels in the general population, heart failure patients, and individuals with acromegaly: differences and projections from meta-analyses-a dual perspective.
Front Cardiovasc Med
October 2024
Department of Endocrinology, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Diabetes, Urumqi, China.
Article Synopsis
- The meta-analysis investigates the relationship between insulin-like growth factor 1 (IGF-1) levels and heart failure (HF), emphasizing IGF-1 as both a biomarker and a potential therapeutic target.
- Analysis of 25 studies revealed that heart failure patients generally have significantly lower IGF-1 levels compared to non-HF controls, suggesting that maintaining intermediate IGF-1 levels may reduce the risk of developing heart failure and related mortality.
- In contrast, treatment-naïve acromegaly patients, who show excessively high IGF-1 levels, have a much higher incidence of both diastolic and systolic heart failure, indicating that elevated IGF-1 can lead to adverse heart outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!